Discontinuation report ATRIPLA
Report ID | 144260 |
Drug Identification Number | 02300699 |
Brand name | ATRIPLA |
Common or Proper name | efavirenz/emtricitabine/tenofovir disoproxil fumarate |
Company Name | GILEAD SCIENCES, LLC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE EFAVIRENZ |
Strength(s) | 300MG 200MG 600MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | Each bottle contains 30 tablets |
ATC code | J05AR |
ATC description | DIRECT ACTING ANTIVIRALS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2021-12-31 |
Actual discontinuation date | 2021-12-31 |
Remaining supply date | 2021-12-31 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | Sufficient supply to meet patient need to discontinuation date. |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 333 LAKESIDE DRIVE FOSTER CITY, CALIFORNIA UNITED STATES 94404 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2022-01-01 | English | Compare |
v3 | 2021-08-17 | French | Compare |
v2 | 2021-08-17 | French | Compare |
v1 | 2021-08-17 | English | Compare |
Showing 1 to 4 of 4